Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Non-Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Non-Current Assets for 4 consecutive years, with $79647.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 7.66% to $79647.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79647.0 through Dec 2025, up 7.66% year-over-year, with the annual reading at $77945.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $79647.0 at Neuphoria Therapeutics, up from $78564.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $85235.9 in Q2 2022, with the low at $73982.0 in Q4 2024.
  • Average Other Non-Current Assets over 4 years is $79016.5, with a median of $79049.4 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets decreased 6.69% in 2023, then grew 7.66% in 2025.
  • Over 4 years, Other Non-Current Assets stood at $85235.9 in 2022, then fell by 6.69% to $79534.9 in 2023, then fell by 6.98% to $73982.0 in 2024, then grew by 7.66% to $79647.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $79647.0, $78564.0, and $77945.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.